Skip to content

The Impact of Mobile APP Intervention ( iCKD APP) on Chronic Kidney Disease Care

The Impact of Mobile APP Intervention ( iCKD APP) on Chronic Kidney Disease Care: A Multicenter, Randomized, Open, Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03649516
Enrollment
101
Registered
2018-08-28
Start date
2018-06-26
Completion date
2020-08-31
Last updated
2021-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Hypertension

Keywords

mHealth, Mobile application, Chronic Kidney Diseases

Brief summary

* Apply Mobile APP Intervention ( iCKD APP) to current chronic kidney disease care program. * Conduct a randomized clinical trial to evaluate the clinical effectiveness of this mobile device on health behavior improvement in chronic kidney disease patients.

Detailed description

A mHealth app (iCKD APP) was designed to assist CKD patients to monitor their home bio-information data. Patients will be randomly assigned into the iCKD APP group(intervention) and traditional care group (control). Participants will be randomized into an 1:1 manner (intervention : control). Random assignment occurred after the consent and initial enrollment interview. Individuals randomized to the iCKD APP will provide with the equipment after randomization. Participants will follow for at least 6 months before the exit interview.

Interventions

DEVICEiCKD APP

Use iCKD APP to upload home bio-information data

Sponsors

Kaohsiung Medical University Chung-Ho Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects are 20 years old and above, Chinese speaking, and able and willing to provide informed consent. * Subjects own mobile devices such as cell phones and tablets. * Subjects were diagnosed with Chronic Kidney Diseases and were taking a single antihypertensive agent for more than three months or they are not receiving treatment but with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.

Exclusion criteria

* starting dialysis or having a kidney transplant (RRT) * participating in other interventional study * cognitively impaired * unable to give consent * life expectancy less than 1 year

Design outcomes

Primary

MeasureTime frameDescription
Compare clinics and home blood pressure3 monthsSystolic and diastolic blood pressure levels measured at both clinics and home will be compared between and within groups at various time points in study period.

Secondary

MeasureTime frameDescription
Achievement of Blood pressure control target3 monthsAchievement of Blood pressure control target will be compared between and within groups at various time points in study period.
The monitor rate of Home Blood pressure3 monthsThe monitor rate of Blood pressure at home will be compared between and within groups at various time points in study period.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026